RHHBY ROCHE HOLDING AG
- 39.270
- -0.070-0.18%
ROCHE HOLDING AG News
Here Are Big Pharma's Leading Blockbuster Makers
Stocks to Watch Next Week: Tesla, Microsoft, Alphabet and Amazon
Analysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF) and Demant (OtherWILLF)
No additional treatment is necessary! Roche (RHHBY.US) innovative therapy has re-applied for approval from the FDA.
On July 19th, Roche (RHHBY.US) released positive data from the Phase 3 clinical trials Pagoda and Pavilion.
Roche Obesity Pill Shows Promising Weight Loss in Early Trial
Roche Holding (SIX:ROG) AG Genussscheine (SWX:ROG) has reported encouraging results from a small Phase 1 trial of its obesity pill, CT-996, showing a 7.3% body weight reduction over four weeks with daily administration – a 6.1 percentage point difference compared to the placebo group.
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy.
Top 20 US stock trading volume on July 18: a well-known analyst said that orders for the Apple iPhone 16 may not have increased.
On Thursday, Nvidia, the top-performing stock in trading volume, rose 2.8%, partially recovering from the huge losses suffered on Wednesday, with a transaction value of $38.113 billion. As of the close of trading on Thursday, the stock had fallen more than 6.3% and may record a decline this week. Tesla, in second place, rose 0.29%, with a transaction value of $27.806 billion. According to the California New Car Dealers Association (CNCDA), Tesla's sales in California in the second quarter of 2024 sharply fell by 24%. The CNCDA reported on Thursday that Tesla's car registration in California has dropped 17% so far this year compared to last year, despite Tesla's.
Eli Lilly, Novo Extend Muti-day Decline in Rare Selloff
Shares of weight loss drugmakers Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) extended a multi-day decline on Thursday, losing billions of dollars in market capitalization for two of the world’s biggest companies.
New Data for Genentech's Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions
– Two-year Phase III data presented at ASRS 2024 show Susvimo's potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with
Roche's (RHHBY.US) bispecific antibody therapy Vabysmo shows long-term clinical trial efficacy.
On July 18, Roche (RHHBY.US) announced four-year new data from the RHONE-X clinical trial of the heavyweight bispecific antibody therapy Vabysmo (faricimab) for the treatment of diabetic macular edema (DME).
Industry shock! Roche's new drug 'scared' the weight loss sector, causing Eli Lilly and co (LLY.US) and Novo Nordisk A/S (NVO.US) to fall.
After Roche (RHHBY.US) announced positive results from its clinical trial of oral weight-loss drugs, the share prices of Eli Lilly and Co (LLY.US) and Novo Nordisk A/S (NVO.US) fell on Wednesday.
Novo Nordisk, Eli Lilly Fall on Data From Roche's Weight-loss Pill
Big Pharma Rally After J&J Earnings
Sell Rating on Roche Holding AG Due to Competitive Concerns and Incomplete CT-966 Data
Genentech's Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study
– More than 90% of patients had absence of DME after four years in a pre-specified exploratory endpoint – – People treated with Vabysmo sustained vision gains and anatomical improvements, with almost 80% receiving
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Corcept Therapeutics (CORT) and Pfizer (PFE)
Roche Stock Jumps on Positive Obesity Drug Trial Results
Pfizer And Roche Advance On Their Weight Loss Drug Journeys
After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE:PFE) moved forward with the once-daily version. On Thursday, Pfizer revealed it will begin studies to evaluate the optimal dose of its weight lose pill during the second half of the year.
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics Inc (NASDAQ:VKTX), and Structure Therapeutics Inc (NASDAQ:GPCR) stocks are trading lower on Wednesday.What happened?
Express News | Benzinga Market Summary: Chip Stocks Fall On Fears Over China Restrictions And Soft Guidance From ASML, Roche Reports Weight Loss Data, Dragging Down Lilly And Novo Nordisk
Analysis
Price Target
No Data
